At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Clinical Trial, Effect of Metformin and Rosiglitazone Over Glucose Homeoastasis in no Diabetic With Metabolic Syndrome Patients.
In Brief
A Phase 3 clinical trial evaluating Metformin group, Rosiglitazone group, and 1 other intervention for Insulin Resistance. Completed, enrolled 30 participants.
Detailed Summary
To compare the effect of insulin sensitizing drugs (metformin and rosiglitazone) over glucose homeostasis (GH) in no diabetic metabolic syndrome individuals. A randomized blinded clinical trial did in patients with metabolic syndrome (n=30), without diabetes. Prior to detailed information and signature of informed consent by patients were done three treatment groups by randomized technique; a) Placebo, b) Metformin (850 mg/day), c) Rosiglitazone (4 mg/day), treatment was administered for 8 weeks. GH was measured before and after treatment using oral glucose tolerance test (OGTT), and IR-index (Homeostatic Model). Determination was performed on weight, size, body mass index, plicometry, blood pressure, fasting glucose levels, triglycerides, HDL-cholesterol and insulin.
Study Details
Timeline
Interventions
We add treatment with Metformin (850 mg/day), treatment was administered for 8 weeks
we add Rosiglitazone (4 mg/day), treatment was administered for 8 weeks
We add Placebo, treatment was administered for 8 weeks